Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has raised concerns in patients with inflammatory bowel disease (IBD), not only due to consequences of coronavirus disease 2019 itself but also as a possible cause of IBD relapse. The main objective of this study was to assess the role of SARS-CoV-2 in IBD clinical recurrence in a cohort of patients undergoing biological therapy. Second, we evaluated the difference in C-reactive protein (CRP) levels between the start and end of the follow-up period (ΔCRP) and the rate of biological therapy discontinuation. Patients with IBD positive for SARS-CoV-2 infection were compared with non-infected patients. IBD recurrence was defined as the need for intensification of current therapy. We enrolled 95 IBD patients with SARS-CoV-2 infection and 190 non-infected patients. During follow-up, 11 of 95 (11.6%) SARS-CoV-2-infected patients experienced disease recurrence compared to 21 of 190 (11.3%) in the control group (p = 0.894). Forty-six (48.4%) SARS-CoV-2-infected patients discontinued biological therapy versus seven (3.7%) in the control group (p < 0.01). In the multivariate analysis, biological agent discontinuation (p = 0.033) and ΔCRP (p = 0.017), but not SARS-CoV-2 infection (p = 0.298), were associated with IBD recurrence. SARS-CoV-2 infection was not associated with increased IBD recurrence rates in this cohort of patients treated with biological agents.

Papa, A., Scaldaferri, F., Covino, M., Tursi, A., Furfaro, F., Mocci, G., Lopetuso, L., Maconi, G., Bibbò, S., Fiorani, M., Laterza, L., Mignini, I., Napolitano, D., Parisio, L., Pizzoferrato, M., Privitera, G., Pugliese, D., Schepis, T., Schiavoni, E., Settanni, C., Vetrone, L., Armuzzi, A., Danese, S., Gasbarrini, A., Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study., <<BIOMEDICINES>>, 2022; 2022 (10(4)): N/A-N/A. [doi:10.3390/biomedicines10040843] [http://hdl.handle.net/10807/201147]

Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study.

Papa A;Scaldaferri F;Covino M;Tursi A;Lopetuso LR;Fiorani M;Laterza L;Mignini I;Napolitano D;Pizzoferrato M;Privitera G;Pugliese D;Schepis T;Schiavoni E;Settanni CR;Vetrone LM;Armuzzi A;Danese S;Gasbarrini A.
2022

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has raised concerns in patients with inflammatory bowel disease (IBD), not only due to consequences of coronavirus disease 2019 itself but also as a possible cause of IBD relapse. The main objective of this study was to assess the role of SARS-CoV-2 in IBD clinical recurrence in a cohort of patients undergoing biological therapy. Second, we evaluated the difference in C-reactive protein (CRP) levels between the start and end of the follow-up period (ΔCRP) and the rate of biological therapy discontinuation. Patients with IBD positive for SARS-CoV-2 infection were compared with non-infected patients. IBD recurrence was defined as the need for intensification of current therapy. We enrolled 95 IBD patients with SARS-CoV-2 infection and 190 non-infected patients. During follow-up, 11 of 95 (11.6%) SARS-CoV-2-infected patients experienced disease recurrence compared to 21 of 190 (11.3%) in the control group (p = 0.894). Forty-six (48.4%) SARS-CoV-2-infected patients discontinued biological therapy versus seven (3.7%) in the control group (p < 0.01). In the multivariate analysis, biological agent discontinuation (p = 0.033) and ΔCRP (p = 0.017), but not SARS-CoV-2 infection (p = 0.298), were associated with IBD recurrence. SARS-CoV-2 infection was not associated with increased IBD recurrence rates in this cohort of patients treated with biological agents.
eng
Papa, A., Scaldaferri, F., Covino, M., Tursi, A., Furfaro, F., Mocci, G., Lopetuso, L., Maconi, G., Bibbò, S., Fiorani, M., Laterza, L., Mignini, I., Napolitano, D., Parisio, L., Pizzoferrato, M., Privitera, G., Pugliese, D., Schepis, T., Schiavoni, E., Settanni, C., Vetrone, L., Armuzzi, A., Danese, S., Gasbarrini, A., Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study., <>, 2022; 2022 (10(4)): N/A-N/A. [doi:10.3390/biomedicines10040843] [http://hdl.handle.net/10807/201147]
File in questo prodotto:
File Dimensione Formato  
biomedicines-10-00843 (2).pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 596.37 kB
Formato Adobe PDF
596.37 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/201147
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact